Primary endpoint not met for BET inhibitor in phase 3 trial

BETonMACE did not meet its primary endpoint, defined by a reduction in major adverse CV events (MACE) with use of apabetalone, in high-risk patients with T2DM, recent ACS and low HDL-c. MACE was defined by the composite of CV death, non-fatal MI and stroke.

Apabetalone was safe and tolerable.

Full study results will be presented at a late-breaking session at AHA 2019.

“We look forward to presenting the full and detailed results of this novel therapeutic approach in a population, that despite optimal care, remains at high risk for additional cardiovascular events,” said Kausik K. Ray, M.D., BETonMACE study chair and Professor of Public Health and Consultant Cardiologist at Imperial College London.

“In addition to the primary results, we look forward to reporting our secondary and exploratory endpoints in the near future,” commented Dr. Michael Sweeney, Senior Vice President, Clinical Development of the Company.

Source: RESVERLOGIX press release September 30, 2019